期 |
栏目 |
标题 |
文件 |
卷 20, 编号 2 (2018) |
Articles |
Case studies on clinical experience of targeted therapy ribociclib in combination with letrozole in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer |
(Rus)
|
卷 23, 编号 1 (2021) |
CLINICAL ONCOLOGY |
Comparison of the efficacy of first-line therapy with different generations of EGFR tyrosine kinase inhibitors in patients with advanced EGFR-associated non-small cell lung cancer: a network meta-analysis of overall survival data |
(Rus)
|
卷 23, 编号 2 (2021) |
CLINICAL ONCOLOGY |
Modern possibilities of immunotherapy in the treatment of extensive-stage small cell lung cancer: experience of durvalumab application. Case report |
(Rus)
|
卷 23, 编号 3 (2021) |
CLINICAL ONCOLOGY |
Malignant neoplasm of the bronchi and lung: Russian clinical guidelines |
(Rus)
|
卷 23, 编号 4 (2021) |
CLINICAL ONCOLOGY |
Multicenter prospective observational post-approval study of safety and efficacy of bevacizumab (Avegra®, BIOCAD) in patients with metastatic colorectal cancer in real world practice: APOLLON-11 and SOYUZ-APOLLON |
(Rus)
|
卷 24, 编号 3 (2022) |
CLINICAL ONCOLOGY |
Malignant neoplasm of the bronchi and lung: Russian clinical guidelines |
(Rus)
|
卷 24, 编号 4 (2022) |
CLINICAL ONCOLOGY |
Real-world efficacy of the first line therapy with prolgolimab in patients with metastatic melanoma: interim results of the FORA (FOrteca Real practice Assessment) observational study |
(Rus)
|
卷 25, 编号 3 (2023) |
CLINICAL ONCOLOGY |
Efficacy and safety of nurulimab+prolgolimab with continued prolgolimab therapy compared to prolgolimab alone as first-line therapy in patients with unresectable or metastatic melanoma: final results of the phase II OBERTON clinical study |
(Rus)
|
卷 26, 编号 1 (2024) |
Articles |
Final data on the efficacy of the FORA study (FOrteca Real practice Assessment): a multicenter prospective observational study on the real-world efficacy of prolgolimab in patients with metastatic melanoma in Russia |
(Rus)
|